STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
29
10
2018
revised:
12
12
2018
accepted:
14
12
2018
pubmed:
15
1
2019
medline:
15
1
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription with many important functions, including regulation of cell proliferation, differentiation, survival, angiogenesis, and immune response. In this study, we have compared by means of RNAscope technology STAT3 RNA expression in human DLBCL in a selected group of activated B-cell-like DLBCL (ABC-DLBCL) patients with another group of germinal center B-cell-like DLBCL (GBC-DLBCL) patients. The results have shown that ABC DLBCL tissue samples contained a significantly higher number of STAT3-positive cells as compared with GCB tissue samples. Moreover, by means of confocal immunofluorescence analysis, we have observed that tumor vessels in ABC samples appeared lined by endothelial cells expressing both FVIII and STAT3 signals, while in GCB samples, only few vessels coexpressed FVIII and STAT3. These data confirm other reports showing that STAT3 is highly expressed and activated in ABC-DLBCL and our previously published data demonstrating that, in primary central nervous system lymphoma, tumor vessels appeared lined by endothelial cells expressing both FVIII and STAT3.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription with many important functions, including regulation of cell proliferation, differentiation, survival, angiogenesis, and immune response.
MATERIALS AND METHODS
METHODS
In this study, we have compared by means of RNAscope technology STAT3 RNA expression in human DLBCL in a selected group of activated B-cell-like DLBCL (ABC-DLBCL) patients with another group of germinal center B-cell-like DLBCL (GBC-DLBCL) patients.
RESULTS
RESULTS
The results have shown that ABC DLBCL tissue samples contained a significantly higher number of STAT3-positive cells as compared with GCB tissue samples. Moreover, by means of confocal immunofluorescence analysis, we have observed that tumor vessels in ABC samples appeared lined by endothelial cells expressing both FVIII and STAT3 signals, while in GCB samples, only few vessels coexpressed FVIII and STAT3.
CONCLUSIONS
CONCLUSIONS
These data confirm other reports showing that STAT3 is highly expressed and activated in ABC-DLBCL and our previously published data demonstrating that, in primary central nervous system lymphoma, tumor vessels appeared lined by endothelial cells expressing both FVIII and STAT3.
Identifiants
pubmed: 30639963
pii: S1936-5233(18)30548-5
doi: 10.1016/j.tranon.2018.12.008
pmc: PMC6370997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
545-549Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Clin Cancer Res. 2003 Jan;9(1):316-26
pubmed: 12538484
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Blood. 2008 Feb 1;111(3):1515-23
pubmed: 17951530
Int J Oncol. 2010 Jul;37(1):103-10
pubmed: 20514402
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
J Hematol Oncol. 2011 Aug 01;4(1):31
pubmed: 21806788
Semin Diagn Pathol. 2011 May;28(2):167-77
pubmed: 21842702
Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):551-64
pubmed: 21860391
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
Neuro Oncol. 2012 Sep;14(9):1136-45
pubmed: 22753228
Int J Oncol. 2013 Jul;43(1):219-27
pubmed: 23612755
Cancers (Basel). 2014 Feb 10;6(1):376-95
pubmed: 24518612
Clin Cancer Res. 2014 Oct 1;20(19):5113-23
pubmed: 25124685
Oncotarget. 2017 May 9;8(19):31254-31269
pubmed: 28415725
Oncotarget. 2017 Aug 4;8(40):69139-69161
pubmed: 28978186
Nat Commun. 2018 Sep 12;9(1):3696
pubmed: 30209389
Genes Dev. 1998 Jul 1;12(13):2048-60
pubmed: 9649508